ClinicalTrials.gg
CompletedNCT04090229Updated Jan 12, 2022

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

A Phase 1 interventional study of ASLAN004 and ASLAN004 Placebo in Atopic Dermatitis, sponsored by ASLAN Pharmaceuticals. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by ASLAN Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
339th of 544
52 · median 96
Started
2019
with 57 others
Phase 1
82 of 639
10 open now
Registered
345th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 339th largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 82 in phase 1, and was the 345th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

A Phase 1B, multi-center, double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) clinical study is designed to evaluate ASLAN004 versus placebo in patients who have moderate-severe AD. The treatment period duration will be 8 weeks with a 12-week follow-up period after the end of treatment.

Read the detailed description

The study is designed as a MAD escalation in up to 3 cohorts of patients, followed by a cohort expansion to further confirm the safety and tolerability of the selected dose, prior to further investigation in Phase 2 studies. The cohort expansion will also support the assessment of the trial's secondary efficacy objectives. Approximately 50 patients are planned to be enrolled across the entire study.

Approximately 24 patients are planned to be enrolled in the initial MAD escalation, with a maximum of 3 ascending dose levels (low, medium and high) of ASLAN004 (Cohorts 1-3). In all dose cohorts, 8 patients will be randomized in a 3:1 ratio to receive ASLAN004 (at specified cohort dose, n=6) or matching placebo (n=2). Additional cohorts may be optional depending on the data from the preceding cohort.

An expansion cohort (Cohort 4) of approximately 27 patients is planned and will be randomized in a 2:1 ratio to receive ASLAN004 (n=18) or matching placebo (n=9). The rationale for this is to provide greater assurance about the safety and tolerability of the selected dose level, and to provide preliminary estimates of the PD and clinical effects at this dose, prior to further dose and schedule finding work in Phase 2 studies.

A total of 8 subcutaneous injections of ASLAN004 or matching placebo will be administered according to a weekly schedule of injection from Day 1 (baseline visit) to Day 50 (Week 7) of the study. Patients will be closely monitored and observed for a period of 30 minutes after each injection of study drug (all visits). The clinical assessments and blood sampling for safety laboratory tests, PK analysis, ADA assays, and biomarkers will be performed at each visit as noted in the Schedule of Assessments. The treatment period will end at the last day of Week 8 (ie., Day 56) after which patients will be followed every week for 12 weeks for safety, PK parameters, ADA, and PD marker assessments. In the event that patients develop adverse events (AEs)/serious AEs (SAEs) which are determined as definitely related, probably related, or possibly related to ADA, and/or patients have a positive ADA result, additional unscheduled sampling of ADA may be performed during the study or after Day 141, as deemed clinically necessary. The exact timepoints for ADA sampling after Day 141 will be discussed between the Investigator and Sponsor for each case.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients who are of or older than the legal age in participating countries, who are able to read and understand, and willing to sign the form.
  2. Willing and able to comply with clinic visits and study-related procedures.
  3. Have a clinical diagnosis of chronic atopic dermatitis (per Eichenfield revised criteria of Hanifin and Rajka) that has been present for at least 3 years before the screening visit.
  4. Have an IGA score of ≥3 at the screening and baseline visits.
  5. Have ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits.
  6. Have an EASI score ≥16 at the screening and baseline visits.
  7. Have a history of inadequate response to a stable (≥1 month) regimen of topical or calcineurin inhibitors as treatment for AD within 3 months before the screening visit.
  8. Have applied a stable dose of an additive, basic, bland topical emollient (moisturizer) twice daily for at least 7 days before Randomization.

Exclusion criteria

Exclusion Criteria:

  1. Have received previous treatment with therapeutic agents targeting ligand or receptors of IL-4 or IL-13, including but not limited to dupilumab, lebrikizumab, or tralokinumab.
  2. Have inadequate organ and hematological function at the screening visit (as per protocol)
  3. Have uncontrolled blood pressure at the screening visit based on clinical judgment of the Investigator.
  4. Have a chest radiograph at Screening or within 3 months before the screening visit with results consistent with prior or current tuberculosis infection (including but not limited to apical scarring, apical fibrosis, or multiple calcified granuloma). This does not include non caseating granulomata. QuantiFERON gold standard may be conducted per standard practice at the site.
  5. Have a known history of (HIV), or infection or positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody HBcAb), positive Hepatitis C antibody (HCV) at the screening visit.
  6. Have a known or suspected history of , including history of invasive opportunistic infections such as tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jiroveci, aspergillosis despite infection resolution; JC virus (progressive multifocal leukoencephalopathy).
  7. Have received treatment with topical , tacrolimus, and/or pimecrolimus within 1 week before Randomization.
  8. Have received treatment with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products (eg., Atopiclair®, MimyX®, Epicerum®, Cerave®, etc) within 1 week before Randomization.
  9. Have had systemic treatment for AD with cyclosporine, mycophenolate-mofetil, interferon gamma (IFN-γ), phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), azathioprine, or methotrexate within 4 weeks before Randomization.
  10. Have had treatment with leukotriene inhibitors within 4 weeks before Randomization.
  11. Have had treatment with systemic corticosteroids within 4 weeks before Randomization.
  12. Have had treatment with small molecule drugs (eg., tofacitinib) within 8 weeks before Randomization.
  13. Have had treatment with biologics other than those targeting ligand or receptors of IL-4 or IL-13 within 8 weeks before Randomization.
  14. Have had treatment with within 8 weeks before Randomization.
  15. Have had treatment with allergen immunotherapy within 6 months before Randomization.
  16. Have had a regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the screening visit.
  17. Requirement of more than 2 bleach baths per week during study participation.
  18. Have chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before the screening visit, or superficial skin infections within 1 week before the screening visit.
  19. Presence of skin comorbidities that may interfere with study assessments.
  20. Have a history or evidence of any active or suspected parasitic infection (other than treated trichomoniasis) within the 4 weeks before Randomization or has travelled within the past 3 months of Randomization to areas of high parasitic exposure (based on Centers for Disease Control and Prevention [CDC] travel notice alert Level 2 and warning Level 3).
  21. Have a history of within 5 years before Randomization with the following exceptions: patient with a history of cured in situ carcinoma of the cervix, and/or non- squamous or basal cell carcinoma of the skin are allowed.
  22. Have any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor's Medical Monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results.
  23. Have a history of alcohol or drug abuse within 2 years of the screening visit.
  24. Have scheduled or anticipate any surgical procedure during study participation and/or hospitalization for any reason within 60 days of Screening.
  25. Pregnant or breastfeeding women.
  26. Patients who are unwilling to use adequate , if of and sexually active. For females, adequate birth control implies: use of hormonal contraceptives, intrauterine devices (IUD), or double barrier contraception (condom + diaphragm, condom or diaphragm + spermicidal gel or foam). For males, adequate birth control implies: use of double barrier contraception (condom + diaphragm, condom or diaphragm + spermicidal gel or foam). Abstinence is also accepted if this is the normal habit of the patient.
  27. Patients who are dependent on prescription moisturizers.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    ASLAN004

    Drug: ASLAN004

  • Placebo comparator
    ASLAN004 Placebo

    Drug: ASLAN004 Placebo

Interventions

  • Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.

  • DrugASLAN004 Placebo

    Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of multiple ascending doses of ASLAN004: Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs) reported from the administration of study drug on Day 1 until the completion of the study.

    Time frame: Baseline to 12 weeks safety follow up

Secondary outcomes

  1. Percentage change from baseline in Eczema Area and Severity Index (EASI) score weekly up to Week 8.

    Time frame: Baseline up to Week 8

  2. Proportion of patients with 50%, 75%, and 90% improvement in the EASI score (EASI50, EASI75, and EASI90) weekly up to Week 8.

    Time frame: Baseline up to Week 8

  3. Percentage change from baseline in the Pruritus Numerical Rating Scale (NRS) score weekly up to Week 8.

    Time frame: Baseline up to Week 8

  4. Proportion of patients with at least a 4-point improvement in the Pruritus NRS score weekly up to Week 8.

    Time frame: Baseline up to Week 8

  5. Proportion of patients who achieve an Investigator Global Assessment (IGA) score of 0 or 1 weekly up to Week 8.

    Time frame: Baseline up to Week 8

  6. Percentage change from baseline in the Patient-Oriented Eczema Measure (POEM) weekly up to Week 8.

    Time frame: Baseline up to Week 8

  7. Percentage change from baseline in percent body surface area (%BSA) affected weekly up to Week 8.

    Time frame: Baseline up to Week 8

  8. PK parameters throughout the dosing period, and serum concentrations by scheduled timepoints.

    Measurement of area under the curve (AUC) at Week 8 (AUC0-last), maximum observed concentration (Cmax) at Week 1, time to Cmax (tmax) at Week 1, Ctrough throughout the dosing period, and serum concentrations by scheduled timepoints.

    Time frame: Baseline to 12 weeks safety follow up

  9. Change from baseline in PD markers of allergic inflammation (TARC and total IgE) weekly up to Week 8.

    Measurement of absolute values of TARC and total IgE in serum concentration and percentage of change

    Time frame: Baseline up to Week 8

  10. Measurement of ASLAN004 Anti-Drug Antibody over time.

    Measurement of ADA levels in serum

    Time frame: Baseline to 12 weeks safety follow up

07

Study locations

11 sites
  • Center for Dermatology Clinical Research, INC
    Fremont, California 94538, United States
  • First OC Dermatology
    Los Angeles, California 92708, United States
  • Direct Helpers Research Center
    Miami, Florida 33012, United States
  • Paddington Testing Co, INC
    Philadelphia, Pennsylvania 19103, United States
  • Dermatology Treatment and Research Cancer
    Dallas, Texas 75230, United States
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute, Inc.
    Carlton, Victoria 3053, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • National Skin Centre
    Singapore, 308205, Singapore
  • Changi General Hospital
    Singapore, 529889, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Oct 2021, 25 months.

Of 131 phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2019
First posted
Sep 16, 2019
StartActual
Sep 9, 2019
Primary completionActual
Oct 28, 2021
CompletionActual
Dec 3, 2021
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04090229
Lead sponsor
ASLAN Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Sep 9, 2019
Primary completion
Oct 28, 2021
Completion
Dec 3, 2021
Last update
Jan 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ASLAN004

Start the discussion